Synaptogenix, Inc.

Synaptogenix, Inc. is a biopharmaceutical company focused on developing a product platform based on the drug candidate Bryostatin-1 for the treatment of Alzheimer's disease. The company also explores therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. generates revenue through its product candidates in pre-clinical and clinical development, as well as through licensing agreements with prominent institutions such as Stanford University and the Icahn School of Medicine at Mount Sinai.

Products

• Bryostatin-1 for Alzheimer's disease treatment

• Therapeutic applications for other neurodegenerative or cognitive diseases